226 related articles for article (PubMed ID: 17693999)
1. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Bakri SJ; Pulido JS; McCannel CA; Hodge DO; Diehl N; Hillemeier J
Eye (Lond); 2009 Jan; 23(1):181-5. PubMed ID: 17693999
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
3. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
4. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
5. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
6. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
7. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
8. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
9. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study.
Knip MM; Välimäki J
Acta Ophthalmol; 2012 May; 90(3):254-8. PubMed ID: 20456259
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Jonas JB; Degenring RF; Kreissig I; Akkoyun I; Kamppeter BA
Ophthalmology; 2005 Apr; 112(4):593-8. PubMed ID: 15808249
[TBL] [Abstract][Full Text] [Related]
11. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection.
Roth DB; Verma V; Realini T; Prenner JL; Feuer WJ; Fechtner RD
Ophthalmology; 2009 Mar; 116(3):455-60. PubMed ID: 19157561
[TBL] [Abstract][Full Text] [Related]
12. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
13. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
15. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
16. Association of OCT angle recess width with IOP response after intravitreal triamcinolone injection.
Singer MA; Groth SL; Sponsel WE; Herro A; Pollard J; Cohen SR; Cohen JH
Retina; 2013 Feb; 33(2):282-6. PubMed ID: 22846803
[TBL] [Abstract][Full Text] [Related]
17. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
18. [Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection].
Dwinger MC; Pieper-Bodeewes I; Eter N; Holz FG
Klin Monbl Augenheilkd; 2005 Aug; 222(8):638-42. PubMed ID: 16118744
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravitreal triamcinolone acetonide on intraocular pressure.
Bakri SJ; Beer PM
Ophthalmic Surg Lasers Imaging; 2003; 34(5):386-90. PubMed ID: 14509462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
